CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. President Donald Trump’s first month in office has been dizzying for U.S ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The round is the second-largest in 2025 among the nearly two dozen venture firms tracked by BioPharma Dive. Eikon has now secured about $1.1 billion in venture dollars since its inception in 2019.

All seven members of Arbutus Biopharma's board have resigned and been replaced by five new members, including the company's new chief executive. The virology-focused biotech company said Tuesday ...

SAN FRANCISCO - GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company with a market capitalization of $4.63 million, has announced the withdrawal of its Registration ...

With the rising global obesity epidemic and the increasing demand for effective weight-loss treatments, the biopharma industry faces mounting pressure to revolutionize GLP-1 manufacturing to meet ...

This brings an inflection point in the biopharma sector, by forging a sustainable pathway for the industry to cater to India’s collective aim of a 45% reduction in emission intensity by 2030 and ...